ATE539767T1 - Adjuvans auf basis von polyinosinsäure/polycytidylsäure - Google Patents
Adjuvans auf basis von polyinosinsäure/polycytidylsäureInfo
- Publication number
- ATE539767T1 ATE539767T1 AT05751955T AT05751955T ATE539767T1 AT E539767 T1 ATE539767 T1 AT E539767T1 AT 05751955 T AT05751955 T AT 05751955T AT 05751955 T AT05751955 T AT 05751955T AT E539767 T1 ATE539767 T1 AT E539767T1
- Authority
- AT
- Austria
- Prior art keywords
- acid
- adjuvant
- eliciting
- immune response
- present
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/205—Rhabdoviridae, e.g. rabies virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2005/000810 WO2006131023A1 (en) | 2005-06-08 | 2005-06-08 | Polyinosinic acid-polycytidylic acid-based adjuvant |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE539767T1 true ATE539767T1 (de) | 2012-01-15 |
Family
ID=37498098
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT05751955T ATE539767T1 (de) | 2005-06-08 | 2005-06-08 | Adjuvans auf basis von polyinosinsäure/polycytidylsäure |
Country Status (18)
Country | Link |
---|---|
US (2) | US7838017B2 (de) |
EP (1) | EP1898948B1 (de) |
JP (1) | JP2008542405A (de) |
KR (1) | KR101203401B1 (de) |
CN (1) | CN1997391A (de) |
AT (1) | ATE539767T1 (de) |
AU (1) | AU2005332599B2 (de) |
BR (1) | BRPI0520330B8 (de) |
CA (1) | CA2605583C (de) |
DK (1) | DK1898948T3 (de) |
ES (1) | ES2380481T3 (de) |
IL (1) | IL187616A (de) |
MX (1) | MX2007015639A (de) |
MY (1) | MY146412A (de) |
PL (1) | PL1898948T3 (de) |
RU (1) | RU2383552C2 (de) |
WO (1) | WO2006131023A1 (de) |
ZA (1) | ZA200709747B (de) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1898948B1 (de) * | 2005-06-08 | 2012-01-04 | Yisheng Biopharma (Singapore) Pte. Ltd. | Adjuvans auf basis von polyinosinsäure/polycytidylsäure |
US20070166800A1 (en) * | 2006-01-13 | 2007-07-19 | Haixiang Lin | Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant |
US20070166239A1 (en) * | 2006-01-13 | 2007-07-19 | Haixiang Lin | Mucosal immunogenic substances comprising a polyinosinic acid - polycytidilic acid based adjuvant |
WO2008133595A1 (en) * | 2007-04-26 | 2008-11-06 | Newbiomed Pika Pte Ltd | Compositions and methods for stimulating an immune response in-vivo and in-vitro |
US20090090367A1 (en) * | 2007-10-03 | 2009-04-09 | Hurley Scott B | Method of contraception |
KR100900837B1 (ko) * | 2007-12-07 | 2009-06-04 | (주)두비엘 | 리포펩타이드와 폴리(i:c)를 아쥬반트로 포함하는 강력한백신 조성물 |
CN101890161B (zh) * | 2008-10-07 | 2014-07-23 | 郝国荣 | 聚核苷酸组合物佐剂 |
CN101780279B (zh) * | 2009-12-22 | 2012-07-11 | 中山大学中山眼科中心 | Toll-like receptor-3激动剂在制备促进伤口愈合的药物中的应用 |
US8569255B2 (en) | 2011-02-02 | 2013-10-29 | Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence | Post-exposure therapy of influenza A infections |
US10172960B2 (en) | 2011-12-15 | 2019-01-08 | Biontech Ag | Particles comprising single stranded RNA and double stranded RNA for immunomodulation |
WO2013087083A1 (en) * | 2011-12-15 | 2013-06-20 | Biontech Ag | Particles comprising single stranded rna and double stranded rna for immunomodulation |
EP2846767B1 (de) | 2012-05-03 | 2022-01-26 | Janssen Sciences Ireland Unlimited Company | Polylnosin-polycytidyl-säure (poly(i:c))-formulierungen zur behandlung von infektionen der oberen atemwege |
CN102949717A (zh) * | 2012-07-06 | 2013-03-06 | 中国疾病预防控制中心病毒病预防控制所 | 一种含poly I:C佐剂的新型乙肝疫苗制剂 |
GB201318858D0 (en) * | 2013-10-25 | 2013-12-11 | Glaxosmithkline Biolog Sa | Calcium fluoride compositions |
GB201318862D0 (en) * | 2013-10-25 | 2013-12-11 | Glaxosmithkline Biolog Sa | Calcium fluoride compositions |
WO2016105274A1 (en) * | 2014-12-23 | 2016-06-30 | Yisheng Biopharma (Singapore) Pte Ltd | A rabies composition comprising pika adjuvant |
CN107198777A (zh) * | 2016-04-01 | 2017-09-26 | 依生生物制药(新加坡)私人有限公司 | 用于治疗癌症的含有聚核苷酸的药物组合物 |
CN109125264B (zh) * | 2017-06-19 | 2020-10-30 | 林海祥 | 一种抗感染抗肿瘤的粘膜免疫制剂 |
CN110944662A (zh) | 2017-08-10 | 2020-03-31 | 依生生物制药(新加坡)私人有限公司 | 用于治疗和/或预防hbv感染的组合物及其用途 |
EP3556398A1 (de) * | 2018-04-16 | 2019-10-23 | Croda Denmark A/S | Phytate zur verwendung als ein biomoleküleabgabe- oder -adsorptionssystem |
AU2019296320B2 (en) * | 2018-06-29 | 2023-10-12 | Xinfu (Beijing) Medical Technology Co., Ltd. | Complex for enhancing immune response |
CN109078180B (zh) * | 2018-06-29 | 2019-05-31 | 信福(北京)医药科技有限公司 | 用于增强免疫响应的复合物 |
CN109701011B (zh) * | 2019-02-26 | 2022-04-05 | 苏文全 | 疫苗复合佐剂系统及其在抗原中的应用 |
CU20220068A7 (es) * | 2020-05-29 | 2023-06-13 | Beijing Yisheng Biotechnology Co Ltd | Composición inmune que contiene ácido polirriboinosínico-polirribocitidílico, un antibiótico o un compuesto poliamino, y un ion positivo |
WO2024102079A1 (en) * | 2022-11-09 | 2024-05-16 | Zeno Therapeutics Pte Ltd | Compositions comprising polyinosinic-polycytidylic acid, epstein-barr (ebv) virus-like particles and ebv-specific car-t cells for improving immune cell therapy |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3692899A (en) * | 1969-12-17 | 1972-09-19 | Us Health Education & Welfare | Inhibition of transplanted tumor growth by polyinosinic-polycytidylic acid in mice |
US3666646A (en) * | 1970-05-15 | 1972-05-30 | Merck & Co Inc | Reduction of molecular weight in polynucleotides using ultrasonic radiation |
US4124702A (en) * | 1971-07-06 | 1978-11-07 | Merck & Co., Inc. | Polynucleotides active as inducers of interferon production in living animal cells |
US3906092A (en) * | 1971-11-26 | 1975-09-16 | Merck & Co Inc | Stimulation of antibody response |
US4186194A (en) | 1973-10-23 | 1980-01-29 | Agence Nationale De Valorisation De La Recherche (Anvar) | Water soluble agents effective as immunological adjuvants for stimulating, in the host the immune response to various antigens and compositions, notably vaccines containing said water soluble agents |
US3952097A (en) * | 1974-09-27 | 1976-04-20 | The United States Of America As Represented By The Department Of Health, Education And Welfare | Nuclease-resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid |
US4024241A (en) * | 1974-09-27 | 1977-05-17 | The United States Of America As Represented By The Secretary Of Health, Education And Welfare | Nuclease-resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid |
FR2321896A1 (fr) * | 1975-08-29 | 1977-03-25 | Anvar | Agents adjuvants immunologiques actifs en solution aqueuse |
US4153684A (en) * | 1976-03-10 | 1979-05-08 | Agence Nationale De Valorisation De La Recherche (Anvar) | Immunizing and anti-infectious adjuvant agents constituted by N-acetyl-muramyl-L-alanyl-D-glutamic acid derivatives |
US4082736A (en) * | 1976-04-26 | 1978-04-04 | Syntex (U.S.A.) Inc. | Novel immunological adjuvant compounds and methods of preparation thereof |
US4082735A (en) | 1976-04-26 | 1978-04-04 | Syntex (U.S.A.) Inc. | Novel immunological adjuvant compounds and methods of preparation thereof |
GB1563561A (en) * | 1976-06-23 | 1980-03-26 | Daiichi Seiyaku Co | Muramyldipeptide derivatives and process for the preparation thereof |
FR2368282A1 (fr) * | 1976-10-22 | 1978-05-19 | Anvar | Adjuvant immunologique constitue par le p-amino-phenyl de n-acetyl-muramyl-l-alanyl-d-isoglutamine |
US4140761A (en) * | 1977-04-11 | 1979-02-20 | The United States Of America As Represented By The Department Of Health, Education & Welfare | Modification of hepatitis B virus infection in chronic carriers of hepatitis B surface antigen |
JPS55111499A (en) * | 1979-02-21 | 1980-08-28 | Takeda Chem Ind Ltd | Glucosamine derivative and its preparation |
CA1185237A (en) * | 1979-02-28 | 1985-04-09 | Yuichi Yamamura | 6-deoxyglucosamine-peptide derivatives, their production and use |
NZ194880A (en) | 1979-09-17 | 1983-07-15 | Merck & Co Inc | Interferon-inducing composition containing modified polyriboinosinic-polyribocytidylic acid |
US4349538A (en) * | 1979-12-07 | 1982-09-14 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Nuclease-resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid |
FR2476488A2 (fr) * | 1980-02-25 | 1981-08-28 | Government Us America | Nouveau complexe hydrophile, resistant aux nucleases, d'acide polyriboinosinique-polyribocytidylique, son procede de preparation et son application comme inducteur d'interferon |
JPS572220A (en) * | 1980-06-09 | 1982-01-07 | Toray Ind Inc | Production of interferon |
US4389395A (en) * | 1981-01-09 | 1983-06-21 | Lerner A Martin | Low molecular weight complex of polyriboinosinic-polyribocytidylic acid and method of inducing interferon |
EP0190833B1 (de) * | 1985-02-07 | 1991-03-27 | Takeda Chemical Industries, Ltd. | Verfahren zur Herstellung von Mikrokapseln |
US4857315A (en) | 1986-09-29 | 1989-08-15 | Mount Sinai Hospital Corporation | Compositions containing golgi alpha-mannosidase II inhibitors |
JPH01186818A (ja) * | 1988-01-18 | 1989-07-26 | Yamasa Shoyu Co Ltd | ポリリボイノシン酸・ポリリボシチジル酸・ポリ−l−リジン複合体製剤 |
CN1056315C (zh) | 1993-05-31 | 2000-09-13 | 林海祥 | 聚肌胞复合物免疫佐剂及含有该佐剂的疫苗 |
US6096291A (en) | 1996-12-27 | 2000-08-01 | Biovector Therapeutics, S.A. | Mucosal administration of substances to mammals |
CA2203843C (en) | 1997-04-28 | 2013-07-23 | Her Majesty The Queen, In Right Of Canada, As Represented By The Ministe R Of National Defence | Liposome-encapsulated poly iclc |
US6514948B1 (en) | 1999-07-02 | 2003-02-04 | The Regents Of The University Of California | Method for enhancing an immune response |
US20070219149A1 (en) | 2003-08-11 | 2007-09-20 | The Research Foundation For Microbial Diseases Of Osaka University | Novel Vaccine Containing Adjuvant Capable Of Inducing Mucosal Immunity |
EP1740611A2 (de) | 2004-04-28 | 2007-01-10 | Paradigm Therapeutics Limited | Ionenkanal |
EP1898948B1 (de) | 2005-06-08 | 2012-01-04 | Yisheng Biopharma (Singapore) Pte. Ltd. | Adjuvans auf basis von polyinosinsäure/polycytidylsäure |
US20070166239A1 (en) * | 2006-01-13 | 2007-07-19 | Haixiang Lin | Mucosal immunogenic substances comprising a polyinosinic acid - polycytidilic acid based adjuvant |
US20070166800A1 (en) * | 2006-01-13 | 2007-07-19 | Haixiang Lin | Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant |
-
2005
- 2005-06-08 EP EP05751955A patent/EP1898948B1/de active Active
- 2005-06-08 KR KR1020077027997A patent/KR101203401B1/ko active IP Right Grant
- 2005-06-08 AT AT05751955T patent/ATE539767T1/de active
- 2005-06-08 CN CNA2005800150972A patent/CN1997391A/zh active Pending
- 2005-06-08 PL PL05751955T patent/PL1898948T3/pl unknown
- 2005-06-08 RU RU2007149551/13A patent/RU2383552C2/ru active
- 2005-06-08 JP JP2008515024A patent/JP2008542405A/ja active Pending
- 2005-06-08 ES ES05751955T patent/ES2380481T3/es active Active
- 2005-06-08 AU AU2005332599A patent/AU2005332599B2/en active Active
- 2005-06-08 MX MX2007015639A patent/MX2007015639A/es active IP Right Grant
- 2005-06-08 CA CA2605583A patent/CA2605583C/en active Active
- 2005-06-08 US US10/551,847 patent/US7838017B2/en active Active
- 2005-06-08 BR BRPI0520330A patent/BRPI0520330B8/pt active IP Right Grant
- 2005-06-08 WO PCT/CN2005/000810 patent/WO2006131023A1/en active Application Filing
- 2005-06-08 DK DK05751955.5T patent/DK1898948T3/da active
-
2006
- 2006-05-26 MY MYPI20062439A patent/MY146412A/en unknown
-
2007
- 2007-11-13 ZA ZA200709747A patent/ZA200709747B/xx unknown
- 2007-11-25 IL IL187616A patent/IL187616A/en active IP Right Grant
-
2010
- 2010-04-13 US US12/759,287 patent/US8303965B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20070160632A1 (en) | 2007-07-12 |
ES2380481T3 (es) | 2012-05-14 |
WO2006131023A1 (en) | 2006-12-14 |
AU2005332599B2 (en) | 2012-02-16 |
PL1898948T3 (pl) | 2012-06-29 |
IL187616A (en) | 2014-02-27 |
AU2005332599A8 (en) | 2008-03-20 |
RU2007149551A (ru) | 2009-07-10 |
CA2605583A1 (en) | 2006-12-14 |
DK1898948T3 (da) | 2012-04-23 |
EP1898948A4 (de) | 2008-07-16 |
US7838017B2 (en) | 2010-11-23 |
RU2383552C2 (ru) | 2010-03-10 |
BRPI0520330B1 (pt) | 2018-04-24 |
US20100297176A1 (en) | 2010-11-25 |
EP1898948A1 (de) | 2008-03-19 |
EP1898948B1 (de) | 2012-01-04 |
CA2605583C (en) | 2013-05-28 |
MX2007015639A (es) | 2008-02-15 |
JP2008542405A (ja) | 2008-11-27 |
CN1997391A (zh) | 2007-07-11 |
KR20080016592A (ko) | 2008-02-21 |
AU2005332599A1 (en) | 2006-12-14 |
US8303965B2 (en) | 2012-11-06 |
ZA200709747B (en) | 2008-11-26 |
BRPI0520330B8 (pt) | 2021-05-25 |
KR101203401B1 (ko) | 2012-11-22 |
BRPI0520330A2 (pt) | 2009-05-05 |
IL187616A0 (en) | 2008-03-20 |
MY146412A (en) | 2012-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE539767T1 (de) | Adjuvans auf basis von polyinosinsäure/polycytidylsäure | |
MY150706A (en) | Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant | |
MY143347A (en) | Mucosal immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant | |
DK1635863T3 (da) | Sammensætninger til udløsning, forbedring og opretholdelse af immunresponser mod MHC-klasse-i-begrænsede epitoper til profylaktiske eller terapeutiske formål | |
CO6260103A2 (es) | Composiciones que comprenden antigenos neumococidos | |
MX2019008303A (es) | Ácido ribonucleico modificado con nucleósidos para inducir una respuesta inmune contra el virus zika. | |
ME01199B (me) | Nove kompozicije adjuvanta | |
ATE426412T1 (de) | Adjuvante influenza-vakzine | |
DK2068918T3 (da) | Vaccinesammensætning omfattende syntetisk adjuvant | |
WO2006068663A3 (en) | Vaccine compositions for treating coronavirus infection | |
WO2007024941A3 (en) | Polyvalent vaccine | |
EP3563865A3 (de) | Prostata-assoziierte antigene und immuntherapieschemata auf impfstoffbasis | |
WO2009143457A3 (en) | Vaccine composition containing synthetic adjuvant | |
WO2006136460A3 (en) | New adjuvant | |
BR112015005987A2 (pt) | vacina, métodos para induzir uma resposta imune contra um antígeno hbv, para proteção de um sujeito da infeção por hbv, para proteger o sujeito que foi diagnosticado com uma infecção por hbv, para induzir uma resposta imune contra um antígeno do hbv, para proteger um indivíduo da infecção pelo hbv, para proteger um indivíduo que foi diagnosticado com infecção pelo hbv, para proteger um indivíduo da infecção pelo hbv, para proteger um indivíduo que foi diagnosticado com infecção pelo hbv, para proteger um sujeito contra infecção por hbv e para proteger o sujeito que foi diagnosticado com uma infecção por hbv, molécula de ácido nucleico, e, proteína | |
AR044696A1 (es) | Composicion de vacunas | |
ATE491720T1 (de) | Impfstoff gegen pasteurella multocida | |
WO2009124309A3 (en) | Vaccines and immunotherapeutics using il-28 and compositions and methods of using the same | |
EA200900738A1 (ru) | Слитые белки, содержащие антигены отторжения опухоли ny-eso-1 и lage-1 | |
EA201200538A1 (ru) | Арабиногалактан для повышения приобретенного иммунного ответа | |
WO2007120860A3 (en) | Nanoemulsion vaccines | |
CU23720A3 (es) | Adyuvante basado en ácido poliinosínico-ácido policitidílico | |
WO2012076157A8 (en) | Malaria vaccines based on pre-erythrocytic antigens from p. falciparum | |
ATE473762T1 (de) | Ein impfstoff |